Hybrid Compounds as Direct Multitarget Ligands: A Review

Author(s): Michelle de Oliveira Pedrosa, Rayssa Marques Duarte da Cruz, Jessika de Oliveira Viana, Ricardo Olimpio de Moura, Hamilton Mitsugu Ishiki, Jose Maria Barbosa Filho, Margareth F. F. M. Diniz, Marcus Tullius Scotti, Luciana Scotti, Francisco Jaime Bezerra Mendonca

Journal Name: Current Topics in Medicinal Chemistry

Volume 17 , Issue 9 , 2017

Become EABM
Become Reviewer


Molecular Hybridization is an approach in rational drug design where new chemical entities are obtained by combining two or more pharmacophoric units from different bioactive compounds into a single molecule. Through this approach, medicinal chemists hope that the new hybrid derivative presents: better affinity and efficacy when compared to the parent drugs; a modified selectivity profile with improvement over pharmacokinetic and pharmacodynamic restrictions; dual or multiple modes of action; reduction of undesirable side effects; decreases in drug-drug interactions; reduced emergence or spread of drug resistance in microorganisms and protozoans; and lower cost. The approach has been successfully used by many research groups around the world and has had very promising results with diseases having multifactorial profiles, like Alzheimer´s, Parkinson´s disease, cancer, inflammation, and hypertension among others. The purpose of this paper is to conduct an updated review of molecular hybridization and multitarget profiling (a rational drug design approach), and its applications to the design and discovery of novel hybrid compounds with anti-inflammatory, antimicrobial, anticancer and antiprotozoal (leishmaniasis, malaria, and schistosomiasis) activities over the last six years.

Keywords: Hybrid compounds, Multitarget, Anti-inflammatory, Antimicrobial, Anticancer, Antiprotozoal.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 12 February, 2017
Page: [1044 - 1079]
Pages: 36
DOI: 10.2174/1568026616666160927160620
Price: $65

Article Metrics

PDF: 66